Ropinirole HCl

【OREQU】Requip® 0.25mg/Tab ATC Code: N04BC04

中文名: 力必平膜衣錠 «GSK»

[OREQU2] Requip PD® 2mg/Tab ATC Code: N04BC04

中文名: 力必平持續性藥效膜衣錠 «GSK»

適應症: 治療自發性帕金森氏症(Idiopathic Parkinson's Disease)。治療原發性腳部躁動症

(Primary Restless Legs Syndrome) •

藥理分類: Anti-Parkinson Agent, Dopamine Agonist.

用法用量: Administration:

• Orally, may be administered without regard to meals; however, taking the drug with food may reduce the occurrence of nausea.

• The Requip PD[®] tablets should be swallowed whole; do not chew, crush, or split.

Safety and efficacy not established in children.

Indications and dosage regimens:

Parkinsonian Syndrome:

Initiate at a low dosage and increase slowly until the maximum therapeutic response is achieved. **MAX dose** 24 mg/day.

Table 1. Ascending-Dose Schedule for Parkinsonian Syndrome

Weeks	Daily Dosage Schedule	Total Daily Dose
1	0.25 mg TID	0.75 mg
2	0.5 mg TID	1.5 mg
3	0.75 mg TID	2.25 mg
4	1 mg TID	3 mg
After week 4		Dose may be increased by 1.5 mg daily each week up to 9 mg daily, and then by up to 3 mg daily each week to a total daily dosage of 24 mg

When ropinirole is used as an adjunct to levodopa, the levodopa dosage may be decreased gradually as tolerated.

Discontinue ropinirole therapy gradually over a period of 1 week. Reduce the frequency of administration from 3 times daily to twice daily for 4 days and then to once daily for 3 days before complete discontinuance of the drug.

Moderate-to-severe primary restless legs syndrome:

Patients were titrated based on clinical response and tolerability.

For RLS, the safety and effectiveness of doses greater than 4 mg once daily have not been established.

Table 2. Dose Titration Schedule for Restless Legs Syndrome

Tuote 2: Bose Traution Senedate for Restress Eegs Syndrome		
Day/Week	Dosage to be taken once daily, 1 to 3 hours before bedtime	
Days 1 and 2	0.25 mg	
Days 3-7	0.5 mg	
Week 2	1 mg	
Week 3	1.5 mg	
Week 4	2 mg	
Week 5	2.5 mg	
Week 6	3 mg	
Week 7	4 mg	

不良反應: 接受 ropinirole 初期治療常見的不良反應包括噁心、嗜睡、腿部水腫、腹痛、嘔吐及暈厥。Ropinirole 作為輔助治療劑,最常見的不良反應包括運動困難、噁心、幻覺、消化不良及意識混淆。

交互作用:

- **SULPIRIDE, METOCLOPRAMIDE**: ↓ efficacy of either drug.
- HALOPERIDOL: loss of antiparkinson efficacy.
- **Warfarin**: ↑ in INR.
- **RISPERIDONE**: ↓ efficacy of ropinirole.

注意事項: 1.應告知病患,可能會發生無任何預警徵兆即突然睡著或日間嗜睡的現象。

- 2.由於 ropinirole 的藥理學作用,對患有嚴重心血管疾病者應小心治療。
- 3.目前尚未研究過 ropinirole 和抗高血壓及抗心律不整藥物並用的影響,並不確知是否可能發生低血壓、心搏徐緩或其它類型的心律不整,故 ropinirole 和這類藥物並用時應特別小心。

懷 孕 期: 1.安全資料尚不足。不建議於懷孕期間使用,除非對病人的益處高於對胎兒的 風險。

2. Current guidelines note that the available information is insufficient to make a recommendation for use in pregnant women.

授 乳 期: 1.Ropinirole 不應用於授乳婦,因為它可能會抑制泌乳。

2. It is not known if ropinirole is present in breast milk.

Ropinirole inhibits prolactin secretion in humans and may potentially inhibit lactation.